Workflow
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
NektarNektar(US:NKTR) ZACKSยท2025-06-25 16:31

Core Insights - Nektar Therapeutics announced that its phase IIb REZOLVE-AD study for rezpegaldesleukin (rezpeg) in treating moderate-to-severe atopic dermatitis met its primary and key secondary endpoints [1][7][8] Group 1: Study Results - The study achieved its primary endpoint of mean improvement in Eczema Area and Severity Score (EASI) from baseline for all three doses of rezpeg compared to placebo at week 16 [2][5] - All doses of rezpeg showed significant improvements in key secondary endpoints, including EASI-75, EASI-50, and mean improvement in Body Surface Area score at week 16 [5][6] - The highest dose of rezpeg also demonstrated statistical significance on EASI-90, indicating a 90% reduction in EASI scores for some patients [6] Group 2: Market Reaction - Following the announcement, Nektar's shares surged by 156.3% and gained an additional 6.8% in after-market trading [2][7] - Year-to-date, Nektar's shares have increased by 75.3%, contrasting with a slight decline of 0.1% in the industry [4] Group 3: Future Plans and Potential - The company plans to present the 16-week induction phase data from the REZOLVE-AD study at a medical conference in 2025 [8] - Management highlighted the potential of rezpeg to become a first and best-in-class immune-modulator for inflammatory skin disorders and other autoimmune conditions [8][9] - Rezpeg is also being studied for alopecia areata, with top-line data expected in the fourth quarter of 2025 [10][11] Group 4: Ownership and Development - Nektar regained full rights to rezpeg from Eli Lilly in April 2023, allowing the company to take charge of its clinical development without royalty payments [11][12]